{"nctId":"NCT00426270","briefTitle":"Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults","startDateStruct":{"date":"2006-06"},"conditions":["Immune Thrombocytopenic Purpura"],"count":116,"armGroups":[{"label":"Octagam 10% 1 g/kg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Octagam 10%"]}],"interventions":[{"name":"Octagam 10%","otherNames":["Human normal immunoglobulin"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) according to standard criteria.\n* Platelet count ≤ 20 x 10\\^9/L.\n\nKey Exclusion Criteria:\n\n* Chronic refractory ITP patients.\n* Thrombocytopenia secondary to other diseases, or drug related thrombocytopenia.\n* Administration of IGIV, anti-D, or other platelet enhancing drugs within 30 days before enrollment.\n* Administration of thrombocyte concentrates within 72 hours before baseline.\n* Experimental treatment (eg, rituximab) within 3 months before enrollment.\n* Prophylactic preoperative treatment for elective splenectomy.\n* Severe liver or kidney disease.\n* Pregnant or nursing female.\n* History of hypersensitivity to blood or plasma derived products.\n* Emergency operation.\n* Live viral vaccination within the last month prior to study entry.\n* Known IgA deficiency and antibodies against IgA.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Clinical Response","description":"A clinical response is defined as an increase in platelet count to ≥ 50\\*10\\^9/L on any day from Day 2 to Day 7.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieve a Clinical Response","description":"A clinical response is defined as an increase in platelet count to ≥ 50\\*10\\^9/L on any day from Day 2 to Day 7.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.08"}]}]}]},{"type":"SECONDARY","title":"Maximum Platelet Count","description":"Platelet count was assessed on Days 2 through 7 and on Days 14, 21, and 63. The maximum measured platelet count is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221.6","spread":"142.66"}]}]}]},{"type":"SECONDARY","title":"Duration of the Clinical Response","description":"The duration of the clinical response was the number of days that the platelet count remained ≥ 50\\*10\\^9/L. Platelet count was assessed on Days 2 through 7 and on Days 14, 21, and 63. A conservative method was used to calculate the duration of the clinical response. For example, if the platelet count was ≥ 50\\*10\\^9/L on Day 7 and dropped below 50\\*10\\^9/L at Day 14, Day 7 was used as the last day to calculate the duration of the clinical response. The same procedure was used if the platelet count dropped below 50\\*10\\^9/L at Day 21 from Day 14 or Day 63 from Day 21.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":"23.88"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With None, Minor, Mild, or Moderate Bleeding at Day 7","description":"The investigator evaluated the severity of bleeding using the following rating scale: None (definitely no haemorrhage of any kind), Minor (few petechiae \\[≤ 100 total\\] and/or ≤ 5 small bruises \\[≤ 3 cm diameter\\], no mucosal bleeding), Mild (many petechiae \\[\\> 100 total\\] and/or \\> 5 large bruises \\[\\> 3 cm diameter\\], no mucosal bleeding), Moderate (overt mucosal bleeding \\[epistaxis, gum bleeding, oropharyngeal blood blisters, menorrhagia, gastrointestinal bleeding, etc\\] that does not require immediate medical attention or intervention).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":116},"commonTop":["Headache","Heart rate increased","Pyrexia","Heart rate decreased","Nausea"]}}}